ADVERTISEMENT
Podcasts
Olaparib Maintenance Therapy for gBRCA-Mutated Pancreatic Cancer
01/03/2020
Recapping a late-breaking abstract from the annual ASCO meeting, Ghassan Abou-Alfa, MD, discusses the POLO trial of olaparib for the treatment of gBRCA-mutated, metastatic pancreatic cancer.
Since the recording of this podcast, olaparib has been approved by the FDA as maintenance therapy for gBRCA-mutated metastatic pancreatic cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement